688222 成都先导
交易中 12-10 14:08:21
资讯
新帖
简况
成都先导（688222）披露股东减持股份结果公告，11月24日股价上涨6.61%
证券之星 · 11-24
成都先导（688222）披露股东减持股份结果公告，11月24日股价上涨6.61%
11月24日成都先导发布公告，股东减持200万股
证券之星 · 11-24
11月24日成都先导发布公告，股东减持200万股
每周股票复盘：成都先导（688222）将召开Q3业绩说明会
证券之星 · 11-16
每周股票复盘：成都先导（688222）将召开Q3业绩说明会
成都先导（688222）披露拟申请注册发行债务融资工具，11月14日股价上涨2.3%
证券之星 · 11-14
成都先导（688222）披露拟申请注册发行债务融资工具，11月14日股价上涨2.3%
成都先导（688222）披露召开2025年第三季度业绩说明会公告，11月10日股价下跌0.17%
证券之星 · 11-10
成都先导（688222）披露召开2025年第三季度业绩说明会公告，11月10日股价下跌0.17%
每周股票复盘：成都先导（688222）股东减持185.94万股，股价上涨12.96%
证券之星 · 11-09
每周股票复盘：成都先导（688222）股东减持185.94万股，股价上涨12.96%
11月7日成都先导发布公告，股东减持185.94万股
证券之星 · 11-07
11月7日成都先导发布公告，股东减持185.94万股
【机构调研记录】红塔红土调研成都先导
证券之星 · 11-03
【机构调研记录】红塔红土调研成都先导
每周股票复盘：成都先导（688222）Q3净利增114.98%
证券之星 · 11-02
每周股票复盘：成都先导（688222）Q3净利增114.98%
成都先导(688222)9月30日股东户数2.07万户，较上期增加13.63%
证券之星 · 10-29
成都先导(688222)9月30日股东户数2.07万户，较上期增加13.63%
成都先导：选举第三届董事会职工代表董事
证券日报网 · 09-15
成都先导：选举第三届董事会职工代表董事
成都先导合作伙伴Bioage Labs启动新型脑渗透性Nlrp3抑制剂Bge-102的1期临床试验
美股速递 · 09-15
成都先导合作伙伴Bioage Labs启动新型脑渗透性Nlrp3抑制剂Bge-102的1期临床试验
成都先导：合作伙伴BioAge启动新颖NLRP3抑制剂BGE-102的I期临床研究
格隆汇 · 09-15
成都先导：合作伙伴BioAge启动新颖NLRP3抑制剂BGE-102的I期临床研究
每周股票复盘：成都先导（688222）2025年限制性股票激励对象公示无异议
证券之星 · 09-14
每周股票复盘：成都先导（688222）2025年限制性股票激励对象公示无异议
每周股票复盘：成都先导（688222）股东减持100万股占比0.2496%
证券之星 · 09-07
每周股票复盘：成都先导（688222）股东减持100万股占比0.2496%
股市必读：9月4日成都先导发布公告，股东减持100万股
证券之星 · 09-05
股市必读：9月4日成都先导发布公告，股东减持100万股
9月3日成都先导涨13.74%，国泰君安量化选股混合发起A基金重仓该股
证券之星 · 09-03
9月3日成都先导涨13.74%，国泰君安量化选股混合发起A基金重仓该股
【机构调研记录】红塔红土调研成都先导
证券之星 · 09-01
【机构调研记录】红塔红土调研成都先导
【机构调研记录】东海基金调研云图控股、成都先导等6只个股（附名单）
证券之星 · 09-01
【机构调研记录】东海基金调研云图控股、成都先导等6只个股（附名单）
每周股票复盘：成都先导（688222）2025年中报净利增390.72%
证券之星 · 08-31
每周股票复盘：成都先导（688222）2025年中报净利增390.72%
公司概况
公司名称：
成都先导药物开发股份有限公司
所属行业：
研究和试验发展
上市日期：
2020-04-16
主营业务：
成都先导药物开发股份有限公司的主营业务是DEL技术相关的药物研发服务。公司的主要产品是小分子及核酸新药。
发行价格：
20.52
{"stockData":{"symbol":"688222","market":"SH","secType":"STK","nameCN":"成都先导","latestPrice":24,"timestamp":1765346901000,"preClose":23.92,"halted":0,"volume":6640857,"delay":0,"changeRate":0.0033,"floatShares":401000000,"shares":401000000,"eps":0.2848,"marketStatus":"交易中","change":0.08,"latestTime":"12-10 14:08:21","open":23.6,"high":24.1,"low":23.38,"amount":158000000,"amplitude":0.0301,"askPrice":24.01,"askSize":9,"bidPrice":24,"bidSize":9,"shortable":0,"etf":0,"ttmEps":0.2848,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765350000000},"marketStatusCode":2,"adr":0,"adjPreClose":23.92,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765330200000,1765337400000],[1765342800000,1765350000000]],"highLimit":26.31,"lowLimit":21.53,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":400680000,"isCdr":false,"pbRate":6.52,"roa":"--","peRate":84.269663,"roe":"6.47%","epsLYR":0.13,"committee":-0.551797,"marketValue":9616000000,"turnoverRate":0.0166,"status":0,"floatMarketCap":9616000000},"requestUrl":"/m/hq/s/688222/wiki","defaultTab":"wiki","newsList":[{"id":"2585460722","title":"成都先导（688222）披露股东减持股份结果公告，11月24日股价上涨6.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585460722","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585460722?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:14","pubTimestamp":1763993667,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，成都先导报收于22.9元，较前一交易日上涨6.61%，最新总市值为91.76亿元。近日，成都先导发布股东拉萨经济技术开发区华博医疗器械有限公司减持股份结果公告。公告显示，本次减持计划实施前，华博器械持有公司股份44,770,579股，占总股本的11.17%。2025年8月5日，公司披露减持计划，华博器械拟通过集中竞价方式减持不超过3,000,000股，占总股本约0.75%，减持期间为2025年8月26日至11月25日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2585246380","title":"11月24日成都先导发布公告，股东减持200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585246380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585246380?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:03","pubTimestamp":1763978585,"startTime":"0","endTime":"0","summary":"证券之星消息，11月24日成都先导发布公告《成都先导:成都先导药物开发股份有限公司股东拉萨经济技术开发区华博医疗器械有限公司减持股份结果公告》，其股东拉萨经济技术开发区华博医疗器械有限公司于2025年9月4日至2025年11月24日间合计减持200.0万股，占公司目前总股本的0.4992%，变动期间该股股价下跌20.49%，截止11月24日收盘报22.9元。股东增减持详情见下表：根据成都先导2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400023749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688222"],"gpt_icon":0},{"id":"2583651647","title":"每周股票复盘：成都先导（688222）将召开Q3业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651647","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651647?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:33","pubTimestamp":1763235191,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，成都先导报收于24.45元，较上周的23.23元上涨5.25%。本周，成都先导11月14日盘中最高价报24.99元。本周关注点公司公告汇总：成都先导将于2025年11月25日召开第三季度业绩说明会。公司公告汇总成都先导药物开发股份有限公司将于2025年11月25日11:00-12:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会，介绍公司当季经营成果及财务状况。成都先导于2025年11月14日召开第二次临时股东会，审议通过上述债务融资工具发行议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2583502430","title":"成都先导（688222）披露拟申请注册发行债务融资工具，11月14日股价上涨2.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502430","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583502430?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:36","pubTimestamp":1763130988,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，成都先导报收于24.45元，较前一交易日上涨2.3%，最新总市值为97.97亿元。近日，成都先导发布2025年第二次临时股东会决议公告，公司于2025年11月14日召开临时股东会，审议通过了关于拟申请注册发行银行间债券市场非金融企业债务融资工具的议案。北京君合（成都）律师事务所对本次会议进行了见证，并出具法律意见书，认为会议的召集、召开程序、出席人员资格、表决程序及表决结果合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400041963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2582877847","title":"成都先导（688222）披露召开2025年第三季度业绩说明会公告，11月10日股价下跌0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582877847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582877847?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:20","pubTimestamp":1762784443,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘，成都先导报收于23.19元，较前一交易日下跌0.17%，最新总市值为92.92亿元。公司近日发布公告称，将于2025年11月25日11:00-12:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会，介绍公司2025年第三季度经营成果及财务状况。投资者可于11月18日至24日通过上证路演中心或投资者关系邮箱提前提问，公司在说明会上将对普遍关注的问题进行回应。说明会结束后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000034589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2582866726","title":"每周股票复盘：成都先导（688222）股东减持185.94万股，股价上涨12.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582866726","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582866726?lang=zh_cn&edition=full","pubTime":"2025-11-09 02:15","pubTimestamp":1762625716,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，成都先导报收于23.23元，较上周的25.23元下跌7.93%。减持期间公司股价上涨12.96%，截至11月3日收盘报25.19元。答：成都先导的超1.2万亿小分子化合物库是全球目前已知规模最大、化合物最多的实体小分子化合物库。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2581009061","title":"11月7日成都先导发布公告，股东减持185.94万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009061","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581009061?lang=zh_cn&edition=full","pubTime":"2025-11-07 19:01","pubTimestamp":1762513302,"startTime":"0","endTime":"0","summary":"证券之星消息，11月7日成都先导发布公告《成都先导:成都先导药物开发股份有限公司股东深圳市钧天投资企业(有限合伙)减持股份结果公告》，其股东深圳市钧天投资企业(有限合伙)于2025年8月28日至2025年11月3日间合计减持185.94万股，占公司目前总股本的0.4641%，变动期间该股股价上涨12.96%，截止11月3日收盘报25.19元。股东增减持详情见下表：根据成都先导2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700032151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2580223746","title":"【机构调研记录】红塔红土调研成都先导","url":"https://stock-news.laohu8.com/highlight/detail?id=2580223746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580223746?lang=zh_cn&edition=full","pubTime":"2025-11-03 08:04","pubTimestamp":1762128240,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月31日披露的机构调研信息，红塔红土近期对1家上市公司进行了调研，相关名单如下：1）成都先导 调研纪要：药物发现前端持续创新，客户对新分子和多样化靶点需求上升。旗下最近一年表现最佳的公募基金产品为红塔红土信息产业精选股票发起式A，最新单位净值为2.07，近一年增长68.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300001982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2580475673","title":"每周股票复盘：成都先导（688222）Q3净利增114.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580475673","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580475673?lang=zh_cn&edition=full","pubTime":"2025-11-02 02:56","pubTimestamp":1762023370,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，成都先导报收于25.23元，较上周的23.34元上涨8.1%。本周，成都先导10月31日盘中最高价报25.49元。股本股东变化截至2025年9月30日，成都先导股东户数为2.07万户，较6月30日增加2488户，增幅13.63%。业绩披露要点2025年前三季度，成都先导实现主营收入3.7亿元，同比增长23.98%；归母净利润9287.22万元，同比增长208.34%；扣非净利润9007.38万元，同比增长420.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688222"],"gpt_icon":0},{"id":"2579920765","title":"成都先导(688222)9月30日股东户数2.07万户，较上期增加13.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579920765","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579920765?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:21","pubTimestamp":1761729715,"startTime":"0","endTime":"0","summary":"证券之星消息，近日成都先导披露，截至2025年9月30日公司股东户数为2.07万户，较6月30日增加2488.0户，增幅为13.63%。在医疗服务行业个股中，成都先导股东户数低于行业平均水平，截至9月30日，医疗服务行业平均股东户数为4.67万户。从股价来看，2025年6月30日至2025年9月30日，成都先导区间涨幅为53.42%，在此期间股东户数增加2488.0户，增幅为13.63%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900035633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2567148273","title":"成都先导：选举第三届董事会职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2567148273","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567148273?lang=zh_cn&edition=full","pubTime":"2025-09-15 22:16","pubTimestamp":1757945760,"startTime":"0","endTime":"0","summary":"证券日报网讯 9月15日晚间，成都先导发布公告称，公司于2025年9月5日召开职工代表大会，经民主讨论、表决通过，选举瞿庆喜先生为公司第三届董事会职工代表董事。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-15/doc-infqqyue1355674.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-15/doc-infqqyue1355674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"1137180932","title":"成都先导合作伙伴Bioage Labs启动新型脑渗透性Nlrp3抑制剂Bge-102的1期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1137180932","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137180932?lang=zh_cn&edition=full","pubTime":"2025-09-15 21:31","pubTimestamp":1757943087,"startTime":"0","endTime":"0","summary":"成都先导合作伙伴Bioage Labs启动新型脑渗透性Nlrp3抑制剂Bge-102的1期临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2567169821","title":"成都先导：合作伙伴BioAge启动新颖NLRP3抑制剂BGE-102的I期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2567169821","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567169821?lang=zh_cn&edition=full","pubTime":"2025-09-15 09:14","pubTimestamp":1757898859,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688222","BK4109","DNA","BK4139","BK7060","BK0216","BK4121","DEL.AU"],"gpt_icon":0},{"id":"2567135603","title":"每周股票复盘：成都先导（688222）2025年限制性股票激励对象公示无异议","url":"https://stock-news.laohu8.com/highlight/detail?id=2567135603","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567135603?lang=zh_cn&edition=full","pubTime":"2025-09-14 03:40","pubTimestamp":1757792424,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，成都先导报收于26.86元，较上周的27.06元下跌0.74%。公司于2025年8月28日至9月6日通过邮件系统公示拟激励对象的姓名和职务，公示期间未收到异议。成都先导药物开发股份有限公司监事会亦对拟激励对象名单发表了核查意见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400000777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2565420517","title":"每周股票复盘：成都先导（688222）股东减持100万股占比0.2496%","url":"https://stock-news.laohu8.com/highlight/detail?id=2565420517","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565420517?lang=zh_cn&edition=full","pubTime":"2025-09-07 01:31","pubTimestamp":1757179867,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘，成都先导报收于27.06元，较上周的25.86元上涨4.64%。本周，成都先导9月4日盘中最高价报30.28元，股价触及近一年最高点。股本股东变化股东增减持9月4日成都先导发布公告，股东拉萨经济技术开发区华博医疗器械有限公司于2025年8月29日至9月3日合计减持100.0万股，占公司目前总股本的0.2496%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700000140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2565300674","title":"股市必读：9月4日成都先导发布公告，股东减持100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2565300674","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565300674?lang=zh_cn&edition=full","pubTime":"2025-09-05 04:12","pubTimestamp":1757016736,"startTime":"0","endTime":"0","summary":"截至2025年9月4日收盘，成都先导报收于27.7元，下跌3.82%，换手率12.27%，成交量49.15万手，成交额13.93亿元。股本股东变化股东增减持9月4日成都先导发布公告，股东拉萨经济技术开发区华博医疗器械有限公司于2025年8月29日至2025年9月3日间合计减持100.0万股，占公司目前总股本的0.2496%，变动期间该股股价上涨20.2%，截止9月3日收盘报28.8元。2025年8月29日至9月3日，华博器械通过集中竞价方式减持公司股份100万股，持股比例由11.17%降至10.92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090500004179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2564365361","title":"9月3日成都先导涨13.74%，国泰君安量化选股混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2564365361","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564365361?lang=zh_cn&edition=full","pubTime":"2025-09-03 16:21","pubTimestamp":1756887692,"startTime":"0","endTime":"0","summary":"证券之星消息，9月3日成都先导涨13.74%创60日新高，收盘报28.8元，换手率12.11%，成交量48.52万手，成交额13.39亿元。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为国泰海通资管的国泰君安量化选股混合发起A。国泰君安量化选股混合发起A目前规模为4.58亿元，最新净值1.4319，较上一交易日下跌2.47%，近一年上涨63.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090300026038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2564863794","title":"【机构调研记录】红塔红土调研成都先导","url":"https://stock-news.laohu8.com/highlight/detail?id=2564863794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564863794?lang=zh_cn&edition=full","pubTime":"2025-09-01 08:04","pubTimestamp":1756685072,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月29日披露的机构调研信息，红塔红土近期对1家上市公司进行了调研，相关名单如下：1）成都先导 个股亮点：公司携手腾讯AILab共同开发新的分子骨架跃迁算法，重视AI在化合物的潜力；公司一直以来都对AI在药物研发领域的进展保持高度关注。旗下最近一年表现最佳的公募基金产品为红塔红土信息产业精选股票发起式A，最新单位净值为1.95，近一年增长97.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100001401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688222"],"gpt_icon":0},{"id":"2564863429","title":"【机构调研记录】东海基金调研云图控股、成都先导等6只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2564863429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564863429?lang=zh_cn&edition=full","pubTime":"2025-09-01 08:01","pubTimestamp":1756684892,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月29日披露的机构调研信息，东海基金近期对6家上市公司进行了调研，相关名单如下：1）云图控股 调研纪要：公司磷复肥业务增长主要来自产品销量增长和结构优化，常规复合肥营收32.41亿元，新型复合肥及磷肥营收39.81亿元。ZGGS34获FDA IND批准，拟用于晚期实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100001252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0027","BK0070","BK0077","688222","002539","BK0216","BK0229"],"gpt_icon":0},{"id":"2563882269","title":"每周股票复盘：成都先导（688222）2025年中报净利增390.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563882269","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563882269?lang=zh_cn&edition=full","pubTime":"2025-08-31 04:02","pubTimestamp":1756584138,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，成都先导报收于25.86元，较上周的22.72元上涨13.82%。本周，成都先导8月29日盘中最高价报26.95元，股价触及近一年最高点。本周关注点业绩披露要点：成都先导2025年中报归母净利润5004.2万元，同比上升390.72%。公司公告汇总：公司拟实施2025年限制性股票激励计划，授予105.22万股，占总股本0.26%。股本股东变化截至2025年6月30日，成都先导股东户数为1.83万户，较3月31日增加2005户，增幅12.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100000549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765346903455,"stockEarnings":[{"period":"1week","weight":0.0617},{"period":"1month","weight":0.0297},{"period":"3month","weight":-0.0645},{"period":"6month","weight":0.4189},{"period":"1year","weight":0.6299},{"period":"ytd","weight":0.9487}],"compareEarnings":[{"period":"1week","weight":0.003},{"period":"1month","weight":-0.022},{"period":"3month","weight":0.0255},{"period":"6month","weight":0.149},{"period":"1year","weight":0.149},{"period":"ytd","weight":0.1664}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都先导药物开发股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"20747人(较上一季度增加13.63%)","perCapita":"19312股","listingDate":"2020-04-16","address":"四川省成都市武侯区高新区科园南路88号1栋3层","registeredCapital":"40068万元","survey":" 成都先导药物开发股份有限公司的主营业务是DEL技术相关的药物研发服务。公司的主要产品是小分子及核酸新药。","listedPrice":20.52},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"成都先导(688222)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供成都先导(688222)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"成都先导,688222,成都先导股票,成都先导股票老虎,成都先导股票老虎国际,成都先导行情,成都先导股票行情,成都先导股价,成都先导股市,成都先导股票价格,成都先导股票交易,成都先导股票购买,成都先导股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"成都先导(688222)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供成都先导(688222)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}